Adding immunotherapy after initial treatment can benefit metastatic lung cancer patients

(University of Pennsylvania School of Medicine) Treating metastatic non-small cell lung cancer (NSCLC) patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy almost tripled the median progression-free survival (PFS) compared to the historical average.

Source: EurekAlert! - Cancer - July 11, 2019 Category: Cancer & Oncology Source Type: news